Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K/A Current report
- 10.1 Registration Rights Agreement, by and Among Actinium Pharmaceuticals, Inc., General Atlantic Investments Limited, and Certain Stockholders, Dated June 30, 2000 (Incorporated by Reference to Exhibit 10.1 to Form 8-K Filed on January 2, 2013).
- 10.2 Amendment No. 1 to June 30, 2000 Registration Rights Agreement, Dated September 29, 2011.
- 10.3 First Amended and Restated Stockholders Agreement, by and Among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, N.V. Organon, and the Stockholders Listed Therein, Dated October 5, 2011.
- 10.4 Second Amended and Restated Investor Rights Agreement, by and Among Actinium Pharmaceuticals, Inc., Actinium Holdings Limited, and the Investors Listed Therein, Dated October 5, 2011.
- 10.5 Placement Agent Engagement Agreement, by and Between Laidlaw & Company (Uk) LTD. and Actinium Pharmaceuticals, Inc., Dated August 7, 2012.
- 10.8 Employment Agreement, Dated January 2, 2006, Between Actinium Pharmaceuticals, Inc. and Dragan Cicic
- 10.9 License, Development and Commercialization Agreement Between Sloan-kettering Institute of Cancer Research, and Actinium Pharmaceuticals, Inc., Dated February 11, 2002; As Amended by the First Amendment Dated August 7, 2006
- 10.10 Phase I/ii Study on the Safety and Efficiency of 225ACAC-HUM195 In Patients with Advanced Myeloid Malignancies with Millennix Oncology, Averion Project, Dated December 6, 2006.
- 10.11 Product Development and Patent License Agreement, Dated February 27, 2003, by and Between Abbott Biotherapeutics and Actinium Pharmaceuticals, Inc.
- 10.12 Clinical Trial Agreement, Dated July 19, 2012, by and Between Fred Hutchinson Cancer Center and Actinium Pharmaceuticals, Inc.
- 10.13 Employment Letter Between Jack V. Talley and Actinium Pharmaceuticals, Inc., Effective August 15, 2012.
- 10.14 Employment Letter Between Enza Guagenti and Actinium Pharmaceuticals, Inc., Effective August 15, 2012.
- 10.15 Clinical Trial Agreement, Dated January 18, 2001, Between Actinium Pharmaceuticals, Inc. and Memorial Sloan Kettering Cancer Center for the Purpose of Conducting a Clinical Trial Entitled ?Phase I/ii Trial of 213BI-M195 and Cytarabine for Acute Myeloid Le
- 10.16 Clinical Trial Agreement with the Trustees of the University of Pennsylvania, Dated November 8, 2012.
- 10.17 Clinical Trial Agreement, Dated March 27, 2012, with Memorial Sloan-kettering Cancer Center.
- 10.18 Clinical Trial Agreement, Dated September 22, 2012, with Johns Hopkins University, Dated September 24, 2012.
- 10.19 License Agreement, Dated June 14, 2012, for BC8 Antibody with Fred Hutchinson Cancer Research Center.
- 10.20 2012 Unit Investor Rights Agreement, Dated December 19, 2012, by and Among Actinium Pharmaceuticals, Inc., the Persons Identified on Exhibit a Attached Thereto Hereto, and the Placement Agent (Defined Below).
- 10.21 Project Agreement, Dated September 30, 2011, Between Actinium Pharmaceuticals, Inc. and Aptiv Solutions, Inc.
- 10.22 Proposal, Dated March 30, 2007, with Isotherapeutics Group, LLC.
- 10.23 Clinical Trial Agreement with the University of Texas M.D. Anderson Cancer, Dated March 1, 2012.
- 10.24 Amendment No. 1 to Research Agreement, Dated November 7, 2012, Between Actinium Pharmaceuticals, Inc. and the University of Texas M.D. Anderson Cancer.
- 10.25 Letter Agreement, Dated June 19, 2011, Between Actinium Pharmaceuticals, Inc. and Sloan-kettering Institute for Cancer Research.
- 10.26 Letter Agreement, Dated April 9, 2010, Between Actinium Pharmaceuticals, Inc. and Sloan-kettering Institute for Cancer Research.
- 10.27 Letter Agreement, Dated July __, 2010, Between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Anti-dilution Rights).
- 10.28 Clinical Trial Agreement, Dated April 12, 2006, with Sloan-kettering Institute for Cancer Research and Memorial Hospital for Cancer and Allied Diseases.
- 10.29 Letter Agreement, Dated __, 2011, Between Actinium Pharmaceuticals, Inc. and Actinium Holdings Limited (Waiver of Registration Rights).
- 99.3 EX-99.3
ATNM similar filings
Filing view
External links
Exhibit 10.24
AMENDMENT No. 1 TO RESEARCH
AGREEMENT
This Amendment No. 1 to Research Agreement ("Amendment") is made and entered into as of November 2, 2012 by and between Actinium Pharmaceuticals, Inc., ("Sponsor") and The University of Texas M.D. Anderson Cancer Center ("Institution"), a member institution of the University of Texas System ("System").
RECITALS
| A. | Sponsor and Institution entered into a Sponsored Research Agreement on August 6, 2012 (the "Agreement"). |
| B. | Sponsor and Institution wish to amend the terms of the Agreement as set forth below. |
NOW, THEREFORE, it is hereby agreed as follows:
| 1. | Amended Exhibit C - part 1 as enclosed replaces the same Exhibit C - part 1 from the Clinical Trial Agreement between The University of Texas M.D. Anderson Cancer Center and Actinium Pharmaceuticals, Inc. dated August 6, 2012. |
| 2. | Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall continue in full force and effect as provided therein. |
IN WITNESS WHEREOF, Sponsor and Institution have entered into this Amendment effective as of the date first set forth above.
| ACTINIUM PHARMACEUTICALS, INC. | THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER | ||||
| By: | /s/ Dragan Cicic | By: | /s/ Renee Gonzales | ||
Dragan Cicic, MD | Renee Gonzales | ||||
| Title: COO/CMO | Title: Assistant Director, Sponsored Programs | ||||
| Date: November 2, 2012 | Date: November 28, 2012 | ||||
Read and Understood | |||
| By: | /s/ Farhad Ravandi-Kashani | ||
| Farhad Ravandi-Kashani,M.D. | |||
| Title: Principal Investigator | |||
| Date: November 26, 2012 | |||
[Notary Seal]
1
2